A10, a web app software company, has generated $187.5m from its initial public offering, which saw Mitsui divested $28.3m of shares.

The kidney disease treatment developer, which has secured funding from Novartis and Novo, has raised $106.9m after underwriters took up the option to buy additional shares.

NephroGenex has closed an initial public offering of 3.1 million shares of common stock.

US-based Genocea Biosciences has raised an approximate net value of $61.4m from selling 5.5 millions shares of common stock at a price of $12 per share in an initial public offering.

US-based biopharmaceutical company Dicerna Pharmaceuticals has closed their initial public offering selling 6.9 million shares of common stock.

Chinese mobile game developer Chukong Technologies is preparing a $150m US initial public offering.

Molecular oncology diagnostics company Biocept has raised $19m in their initial public offering by selling 1.9 million shares of common stock.

Alder, which is developing antibodies to fight migraine and arthritis, secured $38m in a 2012 venture round backed by Novo and TPG, and will use the money from the initial public offering to forward testing.